Ovarian reserve in 26 young women considered by age, by presence or absence of DOR, and by presence or absence of DOR in the subgroup who reported taking hydroxyurea
| . | Cohort by age (n = 26) . | Cohort by ovarian reserve (n = 26) . | Subgroup taking hydroxyurea (n = 15) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 19-25 y (n = 16) . | 26-30 y (n = 10) . | P value . | DOR (n = 5) . | No DOR (n = 21) . | P value . | DOR (n = 5) . | No DOR (n = 10) . | P value . | |
| Median age (IQR), y | 22.5 (21, 24) | 28 (27, 29) | <.01 | 28 (27, 28) | 24 (22, 26) | .12 | 28 (27, 28) | 23 (21, 24) | .06 |
| BMI, median (IQR) | 25 (21, 24) | 28 (27, 29) | .78 | 24 (21, 25) | 25 (21, 26) | .63 | 24 (21, 25) | 24 (21, 26) | .90 |
| Hormonal contraception, n | 6 | 3 | .51 | 2 | 7 | .58 | 2 | 3 | .56 |
| Disease complications | |||||||||
| ASCQ-Me medical history score | 2 (0, 3) | 2 (2, 4) | .5 | 2 (1, 3) | 2 (1, 3) | .93 | 2 (1, 3) | 2 (0, 3.5) | .68 |
| ASCQ-Me pain frequency score | 50 (44, 60) | 54 (42, 56) | .75 | 44 (40, 44) | 56 (48, 60) | .06 | 44 (40, 44) | 52 (44, 55) | .18 |
| Pain episodes in past 12 months | 3 (2, 9) | 7 (2, 8) | .88 | 5 (2, 7) | 6 (2, 9) | .78 | 5 (2, 7) | 6 (2, 9) | .63 |
| Cerebrovascular disease, n | 4 | 0 | .12 | 0 | 4 | .40 | 0 | 2 | .43 |
| Avascular necrosis, n | 3 | 7 | .01 | 3 | 7 | .27 | 3 | 3 | .28 |
| Treatment history | |||||||||
| Current hydroxyurea, n | 10 | 5 | .41 | 5 | 10 | .04 | 5 | 10 | — |
| Ever hydroxyurea use, n | 14 | 10 | .36 | 5 | 19 | .64 | 5 | 10 | — |
| Current transfusions, n | 5 | 3 | .61 | 0 | 8 | .12 | 0 | 3 | .26 |
| Supportive care, n | 4 | 2 | .58 | 0 | 6 | .23 | 0 | 0 | — |
| Hematologic characteristics | |||||||||
| Hemoglobin, g/dL | 8.9 (8.2, 9.8) | 9.3 (8.8, 9.9) | .57 | 8.9 (8.8, 10) | 9 (8.3, 9.8) | .87 | 8.9 (8.8, 10) | 8.5 (8.0, 8.9) | .30 |
| Mean corpuscular volume, fL | 89 (86, 98) | 98 (89, 103) | .09 | 102 (100, 103) | 89 (86, 97) | .01 | 102 (100, 103) | 92 (88, 99) | .03 |
| Absolute neutrophil count, K/μL | 7.9 (4.3, 8.9) | 5.1 (3.6, 8.2) | .25 | 3.7 (1.7, 8.2) | 7.2 (4.6, 8.6) | .27 | 3.7 (1.7, 8.2) | 7.6 (3.1, 9.2) | .33 |
| Ferritin, ng/mL | 466 (151, 1298) | 602 (87, 1982) | 1.00 | 259 (35, 398) | 642 (205, 1982) | .11 | 259 (35, 398) | 552 (232, 980) | .18 |
| Ovarian reserve measures | |||||||||
| Antimullerian hormone, ng/mL | 2.1 (1.7, 4.4) | 1.4 (1.0, 2.0) | .03 | 0.93 (0.9, 1.02) | 2.02 (1.66, 3.58) | <.01 | 0.93 (0.9, 1.02) | 2.54 (1.77, 3.58) | <.01 |
| Antral follicle count, n | 13 (8, 30) | 9 (9, 12) | .46 | 7 (7, 7) | 12 (9, 19) | .23 | 7 (7, 7) | 13 (8, 24) | .28 |
| Follicle stimulating hormone, IU | 5.9 (4.5, 8.6) | 10.1 (9.1, 11.3) | <.01 | 11.3 (10.1, 12) | 6.8 (5.3, 9.2) | <.01 | 11.3 (10.1, 12) | 5.7 (4.5, 7) | <.01 |
| Estradiol, pg/mL | 44 (32, 90) | 41 (39, 53) | .83 | 32 (6, 53) | 46 (33, 102) | .30 | 32 (6, 53) | 46 (34, 95) | .22 |
| Diminished ovarian reserve, n | 1 | 4 | .05 | – | – | – | – | – | – |
| . | Cohort by age (n = 26) . | Cohort by ovarian reserve (n = 26) . | Subgroup taking hydroxyurea (n = 15) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 19-25 y (n = 16) . | 26-30 y (n = 10) . | P value . | DOR (n = 5) . | No DOR (n = 21) . | P value . | DOR (n = 5) . | No DOR (n = 10) . | P value . | |
| Median age (IQR), y | 22.5 (21, 24) | 28 (27, 29) | <.01 | 28 (27, 28) | 24 (22, 26) | .12 | 28 (27, 28) | 23 (21, 24) | .06 |
| BMI, median (IQR) | 25 (21, 24) | 28 (27, 29) | .78 | 24 (21, 25) | 25 (21, 26) | .63 | 24 (21, 25) | 24 (21, 26) | .90 |
| Hormonal contraception, n | 6 | 3 | .51 | 2 | 7 | .58 | 2 | 3 | .56 |
| Disease complications | |||||||||
| ASCQ-Me medical history score | 2 (0, 3) | 2 (2, 4) | .5 | 2 (1, 3) | 2 (1, 3) | .93 | 2 (1, 3) | 2 (0, 3.5) | .68 |
| ASCQ-Me pain frequency score | 50 (44, 60) | 54 (42, 56) | .75 | 44 (40, 44) | 56 (48, 60) | .06 | 44 (40, 44) | 52 (44, 55) | .18 |
| Pain episodes in past 12 months | 3 (2, 9) | 7 (2, 8) | .88 | 5 (2, 7) | 6 (2, 9) | .78 | 5 (2, 7) | 6 (2, 9) | .63 |
| Cerebrovascular disease, n | 4 | 0 | .12 | 0 | 4 | .40 | 0 | 2 | .43 |
| Avascular necrosis, n | 3 | 7 | .01 | 3 | 7 | .27 | 3 | 3 | .28 |
| Treatment history | |||||||||
| Current hydroxyurea, n | 10 | 5 | .41 | 5 | 10 | .04 | 5 | 10 | — |
| Ever hydroxyurea use, n | 14 | 10 | .36 | 5 | 19 | .64 | 5 | 10 | — |
| Current transfusions, n | 5 | 3 | .61 | 0 | 8 | .12 | 0 | 3 | .26 |
| Supportive care, n | 4 | 2 | .58 | 0 | 6 | .23 | 0 | 0 | — |
| Hematologic characteristics | |||||||||
| Hemoglobin, g/dL | 8.9 (8.2, 9.8) | 9.3 (8.8, 9.9) | .57 | 8.9 (8.8, 10) | 9 (8.3, 9.8) | .87 | 8.9 (8.8, 10) | 8.5 (8.0, 8.9) | .30 |
| Mean corpuscular volume, fL | 89 (86, 98) | 98 (89, 103) | .09 | 102 (100, 103) | 89 (86, 97) | .01 | 102 (100, 103) | 92 (88, 99) | .03 |
| Absolute neutrophil count, K/μL | 7.9 (4.3, 8.9) | 5.1 (3.6, 8.2) | .25 | 3.7 (1.7, 8.2) | 7.2 (4.6, 8.6) | .27 | 3.7 (1.7, 8.2) | 7.6 (3.1, 9.2) | .33 |
| Ferritin, ng/mL | 466 (151, 1298) | 602 (87, 1982) | 1.00 | 259 (35, 398) | 642 (205, 1982) | .11 | 259 (35, 398) | 552 (232, 980) | .18 |
| Ovarian reserve measures | |||||||||
| Antimullerian hormone, ng/mL | 2.1 (1.7, 4.4) | 1.4 (1.0, 2.0) | .03 | 0.93 (0.9, 1.02) | 2.02 (1.66, 3.58) | <.01 | 0.93 (0.9, 1.02) | 2.54 (1.77, 3.58) | <.01 |
| Antral follicle count, n | 13 (8, 30) | 9 (9, 12) | .46 | 7 (7, 7) | 12 (9, 19) | .23 | 7 (7, 7) | 13 (8, 24) | .28 |
| Follicle stimulating hormone, IU | 5.9 (4.5, 8.6) | 10.1 (9.1, 11.3) | <.01 | 11.3 (10.1, 12) | 6.8 (5.3, 9.2) | <.01 | 11.3 (10.1, 12) | 5.7 (4.5, 7) | <.01 |
| Estradiol, pg/mL | 44 (32, 90) | 41 (39, 53) | .83 | 32 (6, 53) | 46 (33, 102) | .30 | 32 (6, 53) | 46 (34, 95) | .22 |
| Diminished ovarian reserve, n | 1 | 4 | .05 | – | – | – | – | – | – |
For the ASCQ-Me Medical History Short Form and Acute Pain Episodes Short Form lower score indicates better health. DOR is not associated with collected markers of disease severity. Median (IQR) is reported unless otherwise indicated. Bold values indicate statistical significance.